West Coast USA to West Coast NL for 10X Genomics
Analysts predict that the genomics sector could grow to $24 billion by 2022
California-based 10X Genomics, a leader in single-cell and other areas of genomic analysis in the genomics area, has established its European marketing & sales office in Leiden, the Netherlands.
Genomic analysis enables greater resolution and accelerated understanding of new biology and disease. 10x Genomics builds tools and applications that leverage advances in sequencing along with innovations in hardware, chemistry and software.
10X Genomics began direct sales to Europe, the Middle East and Africa (EMEA) in late 2015, and continues to grow its presence in the EMEA genomics market. From its new location, in Leiden Bio Science Park – a large and mature life sciences cluster in the Netherlands with a focus on translational drug discovery and development, oncology, vaccines and regenerative medicine – 10X Genomics will provide support to its distributed sales teams across the region.
Analysts predict that the genomics sector could grow to $24 billion by 2022 when taking into consideration the significant potential for genomic science to impact areas of research, such as gene editing and precision medicine. As the role of genomics in healthcare becomes increasingly important, having a leading company in this field located in Leiden further strengthens the Dutch Life Sciences & Health ecosystem and its position in the global Life Sciences market.
Vice President of EMEA Sales and Support, Sandy McBean, explains the reason for selecting Leiden: “We see Leiden as an attractive option for inward investment by life science companies due to the excellent infrastructure, including LUMC and the Leiden Bio Science Park. As 10X Genomics expands its business in this region, InnovationQuarter – the regional development organization for the region – can connect us with universities where there is a talented pool of local university graduates with advanced scientific training, for the purposes of recruitment.”
The NFIA and Innovation Quarter worked together to assist 10X Genomics in its evaluation of potential locations within the Netherlands and continue to assist in connecting the company with the various Dutch Life Science & Health clusters.